CTI Clinical trials making cancer more treatable Making Cancer More Treatable
Cancer research products for clinical trials / Investigational Products / Clinical trials for ovarian cancer
CTI products for cancer research
XYOTAX, paclitaxel poliglumex, CT-2103
Pixantrone cancer research drug for non-Hodgkin's lymphoma
Brostallicin cancer treatment for sarcoma
CT-2106
Clinical Studies
Clinical trials for lung cancer
Clinical trials in ovarian cancer
Clinical trial in soft tissue sarcoma
 

Ovarian Cancer Clinical Trials


Now enrolling for:
• A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or OPAXIO™ (formerly known as XYOTAX) versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy


Posted May 13, 2008

Copyright © 2004-2008 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.